119-HR-2715 DC Insider Whip Count Analysis

Breakdown: where the votes are now

H.R. 2715 extends FDA/HHS destruction authority to any refused article that the Secretary determines poses a “significant public health concern,” and creates a new prohibited act for moving items marked for destruction. Committee action and party control set a favorable baseline.

• House: Reported from Energy & Commerce, as amended, 43–0 on May 21, 2026 — a clean bipartisan signal. [1]U.S. House Committee on Energy & Commerce — E&C Roll Call Vote #13 on H.R. 2715…
• House control/context: As of May 13, 2025, Republicans held a narrow House majority (220 R, 213 D, 2 vacant); margins have shifted slightly since but remain tight, making suspension votes the preferred path on consensus bills. [2]Congressional Research Service — CRS: Membership of the 119th Congress — Party…
• Procedural path: Given the unanimous committee vote and bipartisan co‑sponsorship, floor action is likely “under suspension of the rules,” which bars floor amendments and requires a two‑thirds vote — typical for non‑controversial items. [3]Congress.gov (Library of Congress) — CRS: Suspension of the Rules in the House…
• Senate: Companion bill S.3213 (Rick Scott) is pending in HELP, now chaired by Sen. Bill Cassidy — both alignment and venue favor movement once the House ships its bill. Republicans control the chamber (53 R; 45 D; 2 I caucusing with Ds). [4]Congress.gov (Library of Congress) — S.3213 — Destruction of Hazardous Imports…
• Issue scope: The House bill’s text makes the authority general (replacing “drug or device” with “drug, device, or other article”), and adds a prohibited act to block unauthorized movement of goods marked for destruction. [5]Congress.gov (Library of Congress) — H.R. 2715 (IH) — Bill Text PDF

Key legislators and swing votes

Who can move or block the bill — and why.

• House leads: Sponsors Rep. Clay Higgins (R‑LA) and Rep. Troy Carter (D‑LA). Energy & Commerce Chair Brett Guthrie (R‑KY) and Health Subcommittee Chair Morgan Griffith (R‑VA) have already advanced it through subcommittee and full committee. [5]Congress.gov (Library of Congress) — H.R. 2715 (IH) — Bill Text PDF
• Committee vote signals: The 43–0 committee tally included both parties’ members, a strong indicator that enough Democrats will join Republicans to clear a two‑thirds House threshold under suspension. [1]U.S. House Committee on Energy & Commerce — E&C Roll Call Vote #13 on H.R. 2715…
• Senate pathway: Sponsor Sen. Rick Scott (R‑FL); HELP Chair Bill Cassidy (R‑LA). Expect staff-to-staff work to align House and Senate text before floor time. [4]Congress.gov (Library of Congress) — S.3213 — Destruction of Hazardous Imports…
• Senate watch list (possible UC holds): Sens. Rand Paul (R‑KY) and Mike Lee (R‑UT) routinely scrutinize expansions of FDA/administrative authority; either could object to hotline clearance, forcing floor time. [6]Office of Sen. Rand Paul — Sen. Rand Paul press release: Critique of FDA ‘overr…
• Documented Senate supporters: Sen. Cindy Hyde‑Smith (R‑MS) publicly backs S.3213, reflecting broader GOP receptivity. [7]hydesmith.senate.gov

Leadership influence and procedural dynamics

Leadership preferences, committee control, and likely floor mechanics.

• House leadership: Speaker Mike Johnson and Majority Leader Steve Scalise control floor time; bipartisan E&C health packages typically ride the suspension calendar. Minority Leader Hakeem Jeffries’ caucus has backed similar FDA safety items when scoped narrowly. [8]U.S. House of Representatives — Speaker of the House — Mike Johnson
• Senate leadership: Majority Leader John Thune and Minority Leader Chuck Schumer manage clearance; the Senate commonly moves consensus items by unanimous consent after “hotlining.” A single objection (hold) can force floor time. [9]senate.gov
• Executive branch posture: FDA has repeatedly asked Congress for authority to require destruction of refused imports presenting significant public‑health risks (FY25 legislative proposals; reiterated in FY27 budget justifications). That alignment lowers veto risk and speeds post‑enactment rulemaking. [10]U.S. Food and Drug Administration — FDA FY2025 Legislative Proposals — Require…

Interest groups and outside pressure

Support is organized; visible opposition is limited so far, but due‑process concerns could surface.

• Support: Seafood producers and import‑safety coalitions (e.g., Southern Shrimp Alliance; coalition letters to E&C/HELP) are lobbying for passage, citing re‑importation/“port‑shopping” of contaminated goods. [11]Southern Shrimp Alliance — Southern Shrimp Alliance: House Health Subcommittee…
• Process posture: Trade/regulatory analysts flag predictable litigation themes — definitions, notice, and due‑process for owners/consignees; the bill’s requirement that FDA regs align with international agreements helps blunt trade critiques. [12]codifylegalpublishing.com
• Hill coverage: Industry trade press framed the 43–0 committee vote as a bipartisan green light en route to the House floor. [13]SeafoodNews.com — Trade press: E&C advances H.R. 2715 on 43–0 vote toward House…

Assessment: whip count and odds

Bottom line — what passes, where, and how confident we are.

• House vote math: With a 43–0 committee report and no organized opposition, the bill is a good fit for suspension. Expect strong bipartisan yeas; we model a comfortable two‑thirds if brought up on a Monday/Tuesday suspension block. [1]U.S. House Committee on Energy & Commerce — E&C Roll Call Vote #13 on H.R. 2715…
• Senate: HELP should be able to mark up or take the House bill by UC if it’s pre‑cleared in conference and hotline yields no objections. The only real friction is a possible hold from civil‑libertarian Republicans pressing for tighter due‑process language; leadership can overcome with brief floor time if necessary. [4]Congress.gov (Library of Congress) — S.3213 — Destruction of Hazardous Imports…
• Timing: Because FDA has already sought this authority in recent budgets, the measure is considered “implementable,” which helps leadership prioritize it within health safety packages. [10]U.S. Food and Drug Administration — FDA FY2025 Legislative Proposals — Require…

Key procedural and status sources (select)

• House Energy & Commerce full‑committee vote roll sheet (43–0, May 21, 2026). [1]U.S. House Committee on Energy & Commerce — E&C Roll Call Vote #13 on H.R. 2715…
• E&C Dems markup listing showing H.R. 2715 on the May 21 docket. [15]House Energy & Commerce Democrats — E&C Democrats: Full Committee Markup (May 2…
• Subcommittee calendar and leadership remarks from the May 13 Health markup. [16]U.S. House Committee Repository — House Committee Repository: Subcommittee on H…
• Official bill texts/status: H.R. 2715 and S.3213 (Congress.gov). [5]Congress.gov (Library of Congress) — H.R. 2715 (IH) — Bill Text PDF
• Chamber control and leadership: party counts (CRS); Senate and House leadership pages. [2]Congressional Research Service — CRS: Membership of the 119th Congress — Party…
• House suspension procedure (CRS). [3]Congress.gov (Library of Congress) — CRS: Suspension of the Rules in the House…
• FDA budget/legislative proposals requesting destruction authority. [10]U.S. Food and Drug Administration — FDA FY2025 Legislative Proposals — Require…
• Interest‑group backing (Southern Shrimp Alliance; trade press recap). [11]Southern Shrimp Alliance — Southern Shrimp Alliance: House Health Subcommittee…
• Senate hotlining/holds overview (CRS). [14]Congress.gov (Library of Congress) — CRS: ‘Holds’ in the Senate — hotline/unani…